Myovant Sciences to Participate in Two Upcoming Investor Conferences

BASEL, Switzerland, Nov. 15, 2018 /PRNewswire/ -- Myovant Sciences MYOV, a leading clinical-stage biopharmaceutical company focused on women's health and endocrine diseases, today announced its participation in the following upcoming investor conferences:  

• Evercore ISI HealthConX Conference in Boston, MA.  President and Chief Executive Officer, Lynn Seely, M.D., will participate in a fireside chat on Tuesday, November 27, 2018, at 9:30 a.m. ET.  
• Citi's 2018 Global Healthcare Conference in New York, NY.  Myovant will host meetings with investors on Wednesday, December 5 and Thursday, December 6, 2018.

A live webcast of the Evercore presentation will be accessible on the Events page under the Investors and Media section of the Myovant website at www.myovant.com. Please connect to the company's website at least 15 minutes prior to the presentation to ensure adequate time for any software download that may be required to listen to the webcast. A replay of the webcast will be available for 30 days following the conference.

About Myovant Sciences
Myovant Sciences is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of women's health and endocrine diseases. Myovant's lead product candidate is relugolix, an oral, once-daily small molecule that acts as a GnRH receptor antagonist. Myovant has initiated three clinical programs for relugolix consisting of five international Phase 3 clinical trials, two in women with heavy menstrual bleeding associated with uterine fibroids (LIBERTY 1 and 2), two in women with pain associated with endometriosis (SPIRIT 1 and 2), and one in men with advanced prostate cancer (HERO). Myovant is also developing MVT-602, an oligopeptide kisspeptin-1 receptor agonist, that is in Phase 2a development for the treatment of female infertility as part of assisted reproduction. Takeda Pharmaceuticals International AG granted Myovant an exclusive, worldwide license to develop and commercialize relugolix (excluding Japan and certain other Asian countries where Takeda retains exclusive rights) and an exclusive license to develop and commercialize MVT-602 in all countries worldwide. Over time, Myovant intends to expand its development pipeline to include other potential treatments for women's health and endocrine diseases. For more information, please visit Myovant's website at www.myovant.com.

Investor Contact:
Frank Karbe
Chief Financial Officer
Myovant Sciences, Inc.
investors@myovant.com

Media Contact:
Julie Normart
W2O pure
jnormart@w2ogroup.com  
559.974.3245

SOURCE Myovant Sciences, Ltd.